European Union - English - EMA (European Medicines Agency)

les laboratoires servier - pegaspargase - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents, - oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (all) in paediatric patients from birth to 18 years, and adult patients.,

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin, hepatitis b surface antigen, inactivated poliovirus type 1, inactivated poliovirus type 2, inactivated poliovirus type 3, haemophilus influenzae type b polysaccharide (conjugated to tetanus toxoid) - powder and suspension for suspension for injection - not less than 30iu/dose+ not less than 40iu/dose+ 25mcg/dose+ 25mcg/dose+ 8mcg/dose+ 10mcg/dose+ 40d-antigen unit/dose+ 8d-antig

European Union - English - EMA (European Medicines Agency)

nordic group b.v. - methotrexate - arthritis, psoriatic, psoriasis, arthritis, juvenile rheumatoid, arthritis, rheumatoid - antineoplastic agents, - nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to nonsteroidal anti-inflammatory drugs (nsaids) has been inadequate,severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, psoralens and ultraviolet a (puva), and retinoids, and severe psoriatic arthritis in adult patients.

European Union - English - EMA (European Medicines Agency)

csl behring gmbh - alpha1-proteinase inhibitor (human) - genetic diseases, inborn, lung diseases - antihemorrhagics, - respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes pizz, piz(null), pi(null,null), pisz). patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (fev1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.,

New Zealand - English - Medsafe (Medicines Safety Authority)

abbott laboratories (nz) ltd - dosulepin hydrochloride 25mg;   - capsule - 25 mg - active: dosulepin hydrochloride 25mg   excipient: gelatin glycerol magnesium stearate maize starch

New Zealand - English - Medsafe (Medicines Safety Authority)

abbott laboratories (nz) ltd - dosulepin hydrochloride 75mg;   - tablet - 75 mg - active: dosulepin hydrochloride 75mg   excipient: calcium phosphate chalk glucose liquid interwhite markem ink magnesium stearate maize starch povidone sandarac sucrose urethane dimethacrylate luting resin white beeswax

Singapore - English - HSA (Health Sciences Authority)

vantive pte. ltd. - sodium bicarbonate - powder, for solution - 100.00% - sodium bicarbonate 100%

Canada - English - Health Canada

sandoz canada incorporated - digoxin - liquid - 0.05mg - digoxin 0.05mg - cardiotonic agents

Canada - English - Health Canada

pharmascience inc - digoxin - tablet - 0.0625mg - digoxin 0.0625mg - cardiotonic agents

Canada - English - Health Canada

pharmascience inc - digoxin - tablet - 0.125mg - digoxin 0.125mg - cardiotonic agents